for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalent Inc

CTLT.N

Latest Trade

109.58USD

Change

0.53(+0.49%)

Volume

205,197

Today's Range

108.95

 - 

109.80

52 Week Range

69.00

 - 

127.64

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
109.05
Open
109.16
Volume
205,197
3M AVG Volume
22.77
Today's High
109.80
Today's Low
108.95
52 Week High
127.64
52 Week Low
69.00
Shares Out (MIL)
170.34
Market Cap (MIL)
18,575.75
Forward P/E
37.33
Dividend (Yield %)
--

Next Event

Q4 2021 Catalent Inc Earnings Release

Latest Developments

More

Catalent Announces Chief Financial Officer Succession

Catalent, Inc. Reports Q3 EPS $1.27

Moderna And Catalent Announce Collaboration For Vial Filling Of Moderna's Covid-19 Vaccine And Clinical Portfolio

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catalent Inc

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Industry

Biotechnology & Drugs

Contact Info

14 Schoolhouse Rd

SOMERSET, NJ

08873-1213

United States

+1.732.5376200

https://www.catalent.com/

Executive Leadership

John R. Chiminski

Chairman of the Board, Chief Executive Officer

Alessandro Maselli

President, Chief Operating Officer

Thomas P. Castellano

Chief Financial Officer, Senior Vice President

Jonathan Arnold

President - Oral & Specialty Delivery

Karen A. Flynn

President - Biologics and Chief Commercial Officer

Key Stats

1.69 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.5K

2019

2.5K

2020

3.1K

2021(E)

3.9K
EPS (USD)

2018

1.750

2019

1.920

2020

2.110

2021(E)

2.922
Price To Earnings (TTM)
36.85
Price To Sales (TTM)
4.94
Price To Book (MRQ)
5.00
Price To Cash Flow (TTM)
23.84
Total Debt To Equity (MRQ)
79.15
LT Debt To Equity (MRQ)
77.34
Return on Investment (TTM)
8.07
Return on Equity (TTM)
7.03

Latest News

Latest News

AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory - NYT

AstraZeneca Plc is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Baltimore plant to a factory owned by Catalent Inc, the New York Times reported, citing people familiar with the matter.

AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory - NYT

AstraZeneca Plc is in talks with the U.S. government to shift production of its COVID-19 vaccine from a Baltimore plant to a factory owned by Catalent Inc , the New York Times reported on Wednesday, citing people familiar with the matter.

Catalent signs deal with Moderna to speed up U.S. vaccine output

Contract manufacturer Catalent Inc said on Tuesday it had signed an agreement with Moderna Inc to increase the speed of vaccine production at its U.S. facility.

Contract manufacturer Catalent to double Moderna's COVID-19 vaccine production - WSJ

Contract manufacturer Catalent Inc has reached an agreement with Moderna Inc to expand the U.S. production of the vaccine maker's COVID-19 shot, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Catalent says J&J COVID-19 vaccine manufacturing facility received FDA authorization

Catalent Inc said on Tuesday it had received the U.S. regulatory authorization it needs to produce Johnson & Johnson's COVID-19 vaccine at its Bloomington, Indiana facility in the United States.

Catalent to ramp up J&J vaccine production at Italian plant

Catalent is scaling up manufacturing capacity for Johnson & Johnson's COVID-19 vaccine at its Italian plant, addressing some concerns over the drugmaker's ability to meet vaccine supply targets in the European Union.

Catalent plans to expand production of J&J COVID-19 vaccine in Italy: WSJ

Catalent Inc plans to expand its COVID-19 vaccine production in Europe that will enable it to make more doses of Johnson & Johnson's shot, the Wall Street Journal reported https://www.wsj.com/articles/catalent-to-expand-production-of-j-j-covid-19-vaccine-in-italy-11615941463...

J&J waiting on new plant approval to ship high volumes of vaccine: executive

Johnson & Johnson is waiting on regulatory approval of a new, larger plant operated by contract manufacturer Catalent Inc to begin large-scale U.S. deliveries of its just-authorized COVID-19 vaccine following initial shipments this week, a top J&J executive said on Monday.

Moderna says U.S. supply of its vaccine doses have lagged recently

Moderna Inc said on Tuesday the release of some of its COVID-19 vaccine doses to the U.S. government have lagged recently because of "short-term delays" in the final stages of production at its contractor Catalent Inc.

Catalent to make drug substance for AstraZeneca's COVID-19 vaccine candidate

Catalent Inc said on Monday its Maryland facility would make the drug substance used in the COVID-19 vaccine being developed by AstraZeneca Plc and the University of Oxford, starting "late in the third quarter" this year.

Catalent to make active ingredient for AstraZeneca's COVID-19 vaccine candidate

Catalent Inc said on Monday it will manufacture active ingredient for AstraZeneca Plc and the University of Oxford's COVID-19 vaccine candidate.

Moderna eyes third quarter for first doses of potential COVID-19 vaccine with Catalent deal

Moderna Inc <MRNA.O> said on Thursday it was partnering with contract drugmaker Catalent Inc <CTLT.N> to prepare an initial 100 million doses of its coronavirus vaccine for the United States, starting in the third quarter of this year.

BRIEF-Moderna And Catalent Announce Manufacturing Collaboration Of Moderna’S Covid-19 Vaccine Candidate

* MODERNA AND CATALENT ANNOUNCE COLLABORATION FOR FILL-FINISH MANUFACTURING OF MODERNA’S COVID-19 VACCINE CANDIDATE

Moderna names Catalent as manufacturing partner for potential COVID-19 vaccine

Moderna Inc said on Thursday it has partnered with contract drugmaker Catalent Inc to produce 100 million doses of its experimental COVID-19 vaccine starting in the third quarter of 2020.

BRIEF-Viralclear Partners With Catalent On Potential Treatment For COVID-19

* VIRALCLEAR PARTNERS WITH CATALENT ON POTENTIAL TREATMENT FOR COVID-19

AstraZeneca picks Catalent for packaging, supplying potential COVID-19 vaccine

British drugmaker AstraZeneca Plc has struck a deal with contract manufacturer Catalent Inc to help meet its global target of supplying two billion doses of its potential COVID-19 vaccine.

UPDATE 1-AstraZeneca picks Catalent for packaging, supplying potential COVID-19 vaccine

British drugmaker AstraZeneca Plc has struck a deal with contract manufacturer Catalent Inc to help meet its global target of supplying two billion doses of its potential COVID-19 vaccine.

BRIEF-Catalent Signs Deal With Astrazeneca To Manufacture Covid-19 Vaccine Candidate

* CATALENT SIGNS AGREEMENT WITH ASTRAZENECA TO MANUFACTURE COVID-19 VACCINE CANDIDATE

AstraZeneca picks Catalent for packaging potential COVID-19 vaccine

AstraZeneca Plc has struck a deal with Catalent Inc for packaging its potential COVID-19 vaccine, as the British drugmaker prepares to meet its global target of making two billion doses of the vaccine.

BRIEF-Catalent Announces Pricing Of Public Offering Of Common Stock

* CATALENT, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up